Cytokinetics Inc CYTK
We take great care to ensure that the data presented and summarized in this overview for CYTOKINETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYTK
View all-
Black Rock Inc. New York, NY14.7MShares$640 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$520 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$469 Million0.31% of portfolio
-
State Street Corp Boston, MA6.17MShares$269 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.84MShares$124 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.72MShares$119 Million2.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.63MShares$115 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT2.5MShares$109 Million5.18% of portfolio
-
Vestal Point Capital, LP New York, NY2.35MShares$103 Million6.55% of portfolio
-
Pictet Asset Management Sa Geneva 73, V82.25MShares$98.3 Million0.09% of portfolio
Latest Institutional Activity in CYTK
Top Purchases
Top Sells
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Insider Transactions at CYTK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 19
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Bona fide gift
|
Direct |
200
-0.14%
|
-
|
|
Mar 18
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$86,000
$43.58 P/Share
|
|
Mar 18
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Mar 17
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
37,648
-5.3%
|
$1,656,512
$44.52 P/Share
|
|
Mar 17
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
4,389
-4.16%
|
$193,116
$44.38 P/Share
|
|
Mar 17
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
23,675
-21.53%
|
$1,041,700
$44.76 P/Share
|
|
Mar 17
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,900
+26.3%
|
$480,700
$23.26 P/Share
|
|
Mar 14
2025
|
Sung Lee EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,687
+30.51%
|
-
|
|
Mar 14
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,687
+31.72%
|
-
|
|
Mar 14
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
39,450
+21.41%
|
-
|
|
Mar 14
2025
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
116,096
+19.47%
|
-
|
|
Mar 14
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
100
-0.26%
|
$4,500
$45.0 P/Share
|
|
Mar 14
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.26%
|
$2,300
$23.26 P/Share
|
|
Mar 13
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
26,771
-41.55%
|
$1,151,153
$43.62 P/Share
|
|
Mar 06
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
8,228
-7.24%
|
$353,804
$43.27 P/Share
|
|
Mar 06
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,341
-4.93%
|
$143,663
$43.27 P/Share
|
|
Mar 06
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
16,970
-4.45%
|
$729,710
$43.44 P/Share
|
|
Mar 05
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
25,000
-6.16%
|
$1,075,000
$43.23 P/Share
|
|
Mar 04
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.69%
|
$84,000
$42.5 P/Share
|
|
Mar 04
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.67%
|
$20,000
$10.6 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 384K shares |
|---|---|
| Exercise of conversion of derivative security | 272K shares |
| Open market or private sale | 522K shares |
|---|---|
| Payment of exercise price or tax liability | 11K shares |
| Bona fide gift | 2.31K shares |